Omeros Corporation (NASDAQ:OMER) VP Michael A. Jacobsen sold 24,000 shares of the business’s stock in a transaction dated Thursday, June 15th. The stock was sold at an average price of $21.20, for a total transaction of $508,800.00. Following the sale, the vice president now directly owns 2,650 shares of the company’s stock, valued at approximately $56,180. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Omeros Corporation (NASDAQ:OMER) traded up 7.22% during mid-day trading on Friday, hitting $23.75. 4,155,759 shares of the stock traded hands. The firm’s 50-day moving average is $16.37 and its 200-day moving average is $12.93. The company’s market cap is $1.04 billion. Omeros Corporation has a 12-month low of $7.20 and a 12-month high of $25.10.
Omeros Corporation (NASDAQ:OMER) last issued its quarterly earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.01. The firm had revenue of $12.26 million for the quarter, compared to analysts’ expectations of $13.32 million. The business’s quarterly revenue was up 65.2% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.54) earnings per share. Equities research analysts expect that Omeros Corporation will post ($1.32) EPS for the current year.
ILLEGAL ACTIVITY WARNING: This news story was originally posted by Markets Daily and is owned by of Markets Daily. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.themarketsdaily.com/2017/06/17/omeros-corporation-omer-vp-michael-a-jacobsen-sells-24000-shares.html.
A number of analysts have recently commented on OMER shares. FBR & Co reissued a “buy” rating on shares of Omeros Corporation in a research note on Saturday, April 1st. WBB Securities reissued a “buy” rating and set a $75.00 target price on shares of Omeros Corporation in a research note on Thursday, March 30th. Maxim Group reissued a “buy” rating and set a $22.00 target price on shares of Omeros Corporation in a research note on Monday, March 27th. Needham & Company LLC reissued a “buy” rating and set a $22.00 target price (down previously from $24.00) on shares of Omeros Corporation in a research note on Friday, March 17th. Finally, Zacks Investment Research raised shares of Omeros Corporation from a “sell” rating to a “hold” rating in a research note on Wednesday, March 15th. Three investment analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $32.66.
Large investors have recently modified their holdings of the company. Mesirow Financial Investment Management Equity Management increased its stake in shares of Omeros Corporation by 24.8% in the first quarter. Mesirow Financial Investment Management Equity Management now owns 35,000 shares of the biopharmaceutical company’s stock worth $530,000 after buying an additional 6,960 shares during the period. Nationwide Fund Advisors increased its stake in shares of Omeros Corporation by 6.6% in the first quarter. Nationwide Fund Advisors now owns 70,680 shares of the biopharmaceutical company’s stock worth $1,069,000 after buying an additional 4,407 shares during the period. Candriam Luxembourg S.C.A. increased its stake in shares of Omeros Corporation by 33.2% in the first quarter. Candriam Luxembourg S.C.A. now owns 108,370 shares of the biopharmaceutical company’s stock worth $1,639,000 after buying an additional 27,000 shares during the period. Capital Impact Advisors LLC purchased a new stake in shares of Omeros Corporation during the first quarter worth approximately $1,431,000. Finally, Teachers Advisors LLC increased its stake in shares of Omeros Corporation by 9.2% in the fourth quarter. Teachers Advisors LLC now owns 63,334 shares of the biopharmaceutical company’s stock worth $628,000 after buying an additional 5,347 shares during the period. Institutional investors and hedge funds own 45.44% of the company’s stock.
Omeros Corporation Company Profile
Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.
Receive News & Ratings for Omeros Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Corporation and related companies with MarketBeat.com's FREE daily email newsletter.